Atebimetinib Preclinical Data Published in Cancer Research Shows Broad Activity and Favorable Tolerability
IMRX sits 56% above its 52-week low of $2.9.
Summary
Immuneering's atebimetinib demonstrated broad, durable preclinical activity across RAS- and RAF-mutant tumors in a Cancer Research publication. The drug outperformed FDA-approved binimetinib in head-to-head studies and showed resistance to RAF-mediated bypass, a key limitation of other MEK inhibitors. Favorable tolerability was observed, with treated animals maintaining body weight near baseline in a cachexia model. This publication adds mechanistic validation to the ongoing Phase 3 MAPKeeper-301 trial in first-line metastatic pancreatic cancer, reinforcing the drug's differentiated profile. The data supports potential expansion beyond pancreatic cancer into colorectal, lung, and melanoma indications.
At the time of this announcement, IMRX was trading at $4.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $288.5M. The 52-week trading range was $2.90 to $10.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.